These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1389903)

  • 21. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors.
    Sensi M; Grazioli L; Rodolfo M; Parmiani G
    Cancer Immunol Immunother; 1990; 31(1):37-43. PubMed ID: 2306754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
    Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
    Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Precursor phenotype of lymphokine-activated killer cells in the mouse.
    Salup RR; Mathieson BJ; Wiltrout RH
    J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function.
    Iho S; Shau HY; Golub SH
    Cell Immunol; 1991 Jun; 135(1):66-77. PubMed ID: 2018984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine-inducing activity and antitumor effect of a liposome-incorporated interferon-gamma-inducing molecule derived from OK-432, a streptococcal preparation.
    Okamoto M; Gohda H; Ohe G; Yoshida H; Matsuno T; Saito M; Sato M
    J Immunother; 2000 Jan; 23(1):94-103. PubMed ID: 10687142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell cycle assessment of adoptive transferred lymphokine activated killer cells.
    Watanabe R; Tanaka N; Naomoto Y; Moreira LF; Orita K
    Jpn J Clin Oncol; 1994 Apr; 24(2):59-65. PubMed ID: 8158860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients.
    Takahashi K; Harauchi D; Kimura S; Saito S; Monden Y
    Int J Immunopharmacol; 1998 Aug; 20(8):375-88. PubMed ID: 9778099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
    Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
    Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of OK-432 on in vitro secondary responses of the non-adherent cells to IL-2 and OK-432 in cancer patients without tumor burden.
    Fujieda S; Saito H; Isobe Y; Nakagawara G; Nishi O; Nagahara K; Watanabe Y; Hoshino T
    Anticancer Res; 1993; 13(1):21-5. PubMed ID: 8476215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.
    Ohnishi H; Lin KM; Chu TM
    Cancer Res; 1990 Feb; 50(4):1107-12. PubMed ID: 2297759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
    Flexman JP; Manning LS; Robinson BW
    Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
    J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.
    Puri RK; Leland P
    Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
    Grant AJ; Merchant RE; Hall RE
    Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro.
    Findley HW; Nasr S; Afify Z; Hnath R; Waldrep K; Ragab AH
    Cancer Invest; 1990; 8(5):493-500. PubMed ID: 2124946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indirect inhibition of generation of murine lymphokine-activated killer cell activity in splenocyte cultures by interferon-gamma.
    Chao TY; Ohnishi H; Chu TM
    Immunology; 1990 May; 70(1):116-20. PubMed ID: 2113034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
    Gately MK; Anderson TD; Hayes TJ
    J Immunol; 1988 Jul; 141(1):189-200. PubMed ID: 3259967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of low dose total body irradiation (LDTBI) and recombinant human interleukin-2 in mice.
    Fourquet A; Teillaud JL; Lando D; Fridman WH
    Radiother Oncol; 1993 Mar; 26(3):219-25. PubMed ID: 8316651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.